Ensysce Biosciences, Inc.
ENSC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14 | $36 | $24 | $1,422 |
| - Cash | $4 | $1 | $3 | $12 |
| + Debt | $0 | $1 | $4 | $17 |
| Enterprise Value | $11 | $36 | $26 | $1,427 |
| Revenue | $5 | $2 | $3 | $4 |
| % Growth | 133.5% | -11.6% | -28.5% | – |
| Gross Profit | -$2 | -$5 | -$17 | $4 |
| % Margin | -38.6% | -240.1% | -686.1% | 100% |
| EBITDA | -$7 | -$11 | -$24 | -$26 |
| % Margin | -129.2% | -480.4% | -959.9% | -734.3% |
| Net Income | -$8 | -$11 | -$24 | -$29 |
| % Margin | -153.3% | -475.7% | -957.9% | -823.6% |
| EPS Diluted | -4.57 | -4.69 | -139.44 | -355.68 |
| % Growth | 2.6% | 96.6% | 60.8% | – |
| Operating Cash Flow | -$7,502,700 | -$11 | -$18 | -$8 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,502,700 | -$11 | -$18 | -$8 |